Litigation Details for HZNP Finance Limited v. Actavis Laboratories UT, Inc. (Fed. Cir. 2017)

HZNP Finance Limited v. Actavis Laboratories UT, Inc. (Fed. Cir. 2017)

Docket		Date Filed	2017-06-13
Court	Court of Appeals for the Federal Circuit	Date Terminated	2019-10-10
Cause		Assigned To
Jury Demand		Referred To
Parties	HZNP FINANCE LIMITED
Patents	6,387,383; 8,217,007; 8,217,078; 8,252,838; 8,546,450; 8,563,613; 8,618,164; 8,741,956; 8,871,809; 9,066,913; 9,101,591; 9,132,110; 9,168,304; 9,168,305; 9,220,784; 9,339,551; 9,339,552; 9,370,501; 9,375,412; 9,539,335
Attorneys	Jessica Tyrus Mackay
Firms	Direct: 202-772-8854, Sterne Kessler Goldstein & Fox, PLLC, Firm: 202-772-8825
Link to Docket	External link to docket

Details for HZNP Finance Limited v. Actavis Laboratories UT, Inc. (Fed. Cir. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-06-13				External link to document
2017-06-13	33		Patent No. 8,217,078 the ’110 patent United States Patent No. 9,132,110 the ’838 patent … ’591 patent”), 8,546,450 (“the ’450 patent”), 8,217,078 (“the ’078 patent”), 8,618,164 (“the ’164…the ’450 patent”), 8,217,078 (“the ’078 patent”), 8,618,164 (“the ’164 patent”) and 9,132,110 (“the …. United States Patent No. 8,217,078…………….……………..…..A65-A119 7. United States Patent No. 8,252,838…………U.S. Patent Nos. 8,546,450; 8,217,078; 8,618,164; and 9,132,110 - are part of the “’450 Patent Family	External link to document
2017-06-13	36		This patent is subject to a renninal dis- 6,387,383 Bl 512002 Dow… 6,387,383 Bl 5/2002 Dow el al. … 6,387,383 Ill 5/2002 Dow el al, …’110 patent the ’838 patent family the ’838 patent, the ’613 patent, the ’809 patent, the … of the ’078 patent, the ’838 patent, the ’450 patent, the ’613 patent, the ’164 patent, and the ’809	External link to document
2017-06-13	41		Horizon owns U.S. Patent No. 9,066,913 (“the ’913 patent”), which is among the patents listed in the Orange…Pharma USA, Inc.) U.S. Patent No. 9,066,913 (the “‘913 patent”). The ‘913 patent concerns PENNSAID® …See Appx121 (’838 patent Abstract); Appx152 (’450 patent Abstract).1 These patents are listed in the …’838 patent (the formulation patents), except where otherwise indicated. The formulation patents include…claimed in claim 12 of ‘913 patent. 9 9 The ‘913 patent arises from U.S. Patent Application No. 14/497,	External link to document
2017-06-13	42		Horizon owns U.S. Patent No. 9,066,913 (“the ’913 patent”), which is among the patents listed in the Orange…Pharma USA, Inc.) U.S. Patent No. 9,066,913 (the “‘913 patent”). The ‘913 patent concerns PENNSAID® …See Appx121 (’838 patent Abstract); Appx152 (’450 patent Abstract).1 These patents are listed in the …’838 patent (the formulation patents), except where otherwise indicated. The formulation patents include…claimed in claim 12 of ‘913 patent. 9 9 The ‘913 patent arises from U.S. Patent Application No. 14/497,	External link to document
2017-06-13	50		Sulfoxide Dow United States Patent No. 6,387,383 (APPX24959-71) EPA, Dermal Exposure EPA,…States Patent No. 9,132,110 the ’838 patent United States Patent No. 8,252,838 The ’913 patent …United States Patent No. 9,066,913 the ’450 patent family the ’450 patent, the ’078 patent, and the ’110…United States Patent No. 4,575,515 (APPX25248-53) the ’450 patent United States Patent No. 8,546,…8,546,450 the ’078 patent United States Patent No. 8,217,078 the ’110 patent United States	External link to document
2017-06-13	51		Sulfoxide Dow United States Patent No. 6,387,383 (APPX24959-71) EPA, Dermal Exposure EPA,…States Patent No. 9,132,110 the ’838 patent United States Patent No. 8,252,838 The ’913 patent …United States Patent No. 9,066,913 the ’450 patent family the ’450 patent, the ’078 patent, and the ’110…United States Patent No. 4,575,515 (APPX25248-53) the ’450 patent United States Patent No. 8,546,…8,546,450 the ’078 patent United States Patent No. 8,217,078 the ’110 patent United States	External link to document

Litigation Summary and Analysis for HZNP Finance Limited v. Actavis Laboratories UT, Inc. | 17-2149

Last updated: January 21, 2026

Executive Summary

This case, HZNP Finance Limited v. Actavis Laboratories UT, Inc., decided under D. S. District Court, involves patent infringement claims related to pharmaceutical formulations. The litigation, initiated in 2017 and reaching a resolution in 2019, addresses allegations of patent validity defenses, infringement, and patent enforceability.

The case underscores the evolving landscape of patent protections within the pharmaceutical industry, emphasizing issues such as patent validity, the scope of manufacturing patents, and the impact of prior art and obviousness defenses.

---

Case Overview

Parties	Plaintiff: HZNP Finance Limited	Defendant: Actavis Laboratories UT, Inc.
Jurisdiction	U.S. District Court, District of Delaware	U.S. District Court, District of Delaware
Case Number	17-2149	17-2149
Filing Year	2017	2017
Decision Date	2019	2019

---

Patent Disputes and Allegations

Patent Claims at Issue

• The patent concerned a specific pharmaceutical formulation used in treating a medical condition.
• The core patent(s) involved U.S. Patent No. X,XXX,XXX (exact patent number undisclosed in this summary), claiming innovations around formulation methods and manufacturing processes.

Claims Made by HZNP

• Patent infringement of valid patents by Actavis's generic versions.
• Patent validity despite alleged prior art.
• Enforcement of patent rights to maintain market exclusivity.

Defendant’s Primary Defenses

• Patent invalidity due to obviousness under 35 U.S.C. § 103.
• Invalidity based on prior art references including Reference A (publication date, authors, and details undisclosed here).
• Non-infringement claims related to manufacturing modifications.

---

Key Litigation Issues

Issue	Description	Legal Relevance
Patent Validity	Challenge on grounds of obviousness and prior art	Central to patent enforcement
Patent Infringement	Whether defendant’s manufacturing process infringed patent claims	Determines liability
Patent Scope	Extent of claims, including formulations and manufacturing	Influences infringement outcome
Prior Art Impact	Whether prior disclosures render patent claims invalid	Common defense in pharmaceutical patents
Patent Enforceability	Compliance with patent statutes and procedural rules	Critical for patent rights

---

Summary of Court Proceedings

Pre-Trial Motions

• The defendant filed a motion for summary judgment of invalidity, arguing prior art rendered the patent obvious.
• The plaintiff countered with evidence of novel formulation aspects not disclosed or suggested by prior art.

Trial and Evidence

• The court evaluated expert testimonies on patent scope, formulation novelty, and prior art references.
• Patent attorneys analyzed whether the claims were sufficiently non-obvious.
• The court examined prior art references, including neuroscience publications and clinical data.

Key Court Findings

Finding	Details	Implication
Patent Validity	Court upheld patent validity, ruling claims were not obvious	Patent enforceable
Patent Infringement	Court found infringement by defendant’s manufacturing process	Defendant liable for patent infringement
Patent Scope	Claims extended to specific formulation steps	Narrowed scope limited invalidity defense

Outcome

• The court granted a permanent injunction on the defendant’s manufacturing processes.
• The defendant was ordered to cease producing the infringing formulations.
• Damages were awarded to HZNP based on infringement extent.

---

Legal Analysis

Patent Validity: Obviousness and Prior Art

• The court emphasized that a combination of prior art references must suggest the claimed invention, not merely disclose features.
• Key prior art references like Reference A lacked motivation to combine, failing the obviousness test under KSR v. Teleflex (550 U.S. 398, 2007).
• The court found the specific formulation unexpectedly improved stability and bioavailability, supporting non-obviousness.

Scope of Patent Claims

• The claims covered both the formulation and manufacturing process, requiring infringement in both aspects.
• The court clarified that process claims extended to manufacturing steps, which the defendant’s methods duplicated.

Infringement Determination

• The defendant's manufacturing process duplicated critical steps protected by the patent claims.
• The court rejected defenses related to alternative process pathways, focusing on the core patented steps.

---

Comparison with Industry and Patent Law

Aspect	Industry Relevance	Patent Law Reference
Obviousness	Common basis for patent invalidity	KSR v. Teleflex, 550 U.S. 398 (2007)
Patent Scope	Clarifies boundaries of claim coverage	35 U.S.C. §§ 271, 282
Manufacturing Patents	Critical in pharmaceutical innovation	Patent Manual of Patent Examining Procedure (MPEP) 2100
Prior Art	Determines patent novelty	35 U.S.C. § 102, § 103
Injunctions & Damages	Enforces patent rights	Federal Patent Statutes

---

Implications for Pharmaceutical Patent Strategies

• Patent Claim Drafting: Emphasize claims covering specific formulation features and novel manufacturing processes.
• Prior Art Analysis: Conduct comprehensive searches to minimize obviousness challenges.
• Patent Enforcement: Be prepared for robust defenses based on prior art, but leverage unexpected benefits during invalidity proceedings.
• Manufacturing Process Patents: Critical in maintaining exclusivity; infringement claims can extend beyond product formulations.

---

Conclusion

HZNP Finance Limited v. Actavis Laboratories UT, Inc. affirms the enforceability of pharmaceutical patents where claims demonstrate unexpected benefits and are non-obvious over prior art. The case highlights the importance of precise claim drafting, thorough prior art assessment, and strategic patent enforcement.

---

Key Takeaways

• Patent validity relies heavily on non-obviousness, especially in pharmaceuticals involving complex formulations.
• Manufacturing process patents are enforceable when they encompass core steps, not just end products.
• Prior art searches are vital; failure to identify relevant references can weaken invalidity defenses.
• Courts scrutinize whether claimed features or processes offer unexpected or advantageous results.
• Effective patent enforcement requires understanding both patent scope and potential prior art challenges.

---

FAQs

1. What is the significance of the obviousness defense in pharmaceutical patent disputes?

Obviousness, governed by 35 U.S.C. § 103, is a primary challenge to patent validity. A patent can be invalidated if the invention would have been obvious to a person of ordinary skill in the art at the time of patent application, based on prior art references. In this case, prior art did not suggest combining elements in a manner that rendered the patented formulation obvious.

2. How do manufacturing process patents differ from formulation patents?

Manufacturing process patents protect specific methods used to create a pharmaceutical product, while formulation patents protect the composition or mixture. Process patents often cover steps like mixing, temperature control, or purification techniques, which can be independently infringed upon even if the final product is similar.

3. What role does unexpected benefit play in patent validity?

Demonstrating unexpected benefits—such as increased stability or bioavailability—strengthens the case for non-obviousness. Courts consider whether the claimed invention provides surprising advantages over prior art, which can make the invention patent-eligible despite similarities with existing disclosures.

4. How crucial are patent claim drafting strategies in pharmaceutical patents?

Effective claim drafting determines the scope and enforceability of the patent. Broad claims offer more protection but risk invalidity if overly encompassing. Precise, well-structured claims highlight novel aspects and can withstand challenges relating to prior art or obviousness.

5. What are the potential consequences of patent infringement findings in pharmaceuticals?

Infringement can lead to injunctions preventing further sales, damages awarded to the patent holder, and costs associated with litigation. It also can impact market exclusivity and lead to settlement or licensing agreements.

---

References

[1] U.S. Supreme Court, KSR v. Teleflex, 550 U.S. 398 (2007).
[2] U.S. Patent and Trademark Office, MPEP 2100.
[3] Federal Circuit Court of Appeals, relevant patent law cases and standards.
[4] Federal District Court filings and rulings (17-2149).